Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study

The increasing use of biologics is accompanied by a risk of hepatitis B (HBV) and C virus (HCV) reactivation. To determine the predictors of HBV and HCV reactivation in patients with psoriasis receiving biologics. This study screened 2060 patients with psoriasis (3562 treatment episodes) who were ta...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2021-08, Vol.85 (2), p.337-344
Main Authors: Chiu, Hsien-Yi, Chiu, Ying-Ming, Chang Liao, Nien-Feng, Chi, Ching-Chi, Tsai, Tsen-Fang, Hsieh, Chang-Yu, Hsieh, Tsu-Yi, Lai, Kuo-Lung, Chiu, Tsu-Man, Wu, Nan-Lin, Hui, Rosaline Chung-yee, Lee, Chaw-Ning, Wang, Ting-Shun, Chen, Po-Hua, Yang, Chao-Chun, Huang, Yu-Huei
Format: Article
Language:English
Subjects:
biologics
hepatitis B
hepatitis C
immunosuppressant
psoriasis
reactivation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The increasing use of biologics is accompanied by a risk of hepatitis B (HBV) and C virus (HCV) reactivation. To determine the predictors of HBV and HCV reactivation in patients with psoriasis receiving biologics. This study screened 2060 patients with psoriasis (3562 treatment episodes) who were taking biologics from 2009 to 2018. There were 359 patients with psoriasis with HBV (561 treatment episodes) and 61 with HCV infection (112 treatment episodes). During 8809 and 1522 person-months of follow-up, 88 treatment episodes for HBV involved HBV reactivation, and 14 episodes of HCV involved reactivation. The reactivation rate was significantly higher in treatment episodes of chronic HBV infection than in that of occult HBV (34.3% vs 3.2%, P = .001) and resolved HBV (34.3% vs 5.0%, P 
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2019.12.001